<DOC>
	<DOC>NCT00932074</DOC>
	<brief_summary>The purpose of this study is to assess the safety, tolerability and efficacy of KP‑413 topical ointment compared with vehicle ointment in treating adult subjects with atopic dermatitis (AD).</brief_summary>
	<brief_title>A Study to Determine the Safety, Tolerability and Efficacy of KP‑413 in Subjects With Atopic Dermatitis(AD)</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis, Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Has a clear diagnosis of AD meeting the Hanifin and Rajka criteria for AD that involves both the head/neck and the torso/limbs, and affects 530% of the subject's total BSA as determined using the rule of nines Has a Baseline IGSS of 3(moderate) or 4(severe) in the selected treatment area on the torso/limbs, and a Baseline IGSS of 2(mild), 3(moderate) or 4(severe) in the selected treatment area on the head/neck. Female of childbearing potential has a negative pregnancy test and will be using an effective method of contraception during the study. Female who is pregnant, nursing an infant, or planning a pregnancy during the study period. Has a Baseline oozing/crusting score of 3(moderate) or greater at the selected treatment area on the head/neck or torso/limbs. Presence of a concurrent skin condition that could interfere with assessment of treatment. Treatment with any investigational drug or device within 30 days or 5 half lives(whichever is longer) prior to the Baseline visit, or concurrent participation in another clinical trial with an investigational drug or device.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Atopic Dermatitis</keyword>
</DOC>